Patents by Inventor Gordon Powers

Gordon Powers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Electrified vehicle with dual-use storage/cooling compartment
    Patent number: 11964589
    Abstract: An electrified vehicle includes a storage compartment positioned forward of a vehicle passenger cabin and accessible by opening a vehicle hood, a thermally conductive plate or heat exchanger in contact with a bottom surface of the storage compartment and having an associated conduit configured for circulating a working fluid from a vehicle cooling system, and a valve operable to control flow of the working fluid through the conduit. The storage compartment may be filled with a cooling medium, such as ice or dry ice, to provide enhanced cooling during high-demand operation or charging of the vehicle, such as when operating in a performance/track mode, towing a trailer, or in other extreme use scenarios. The valve may be controlled so that the working fluid bypasses the conduit when the storage compartment is used for cargo and/or enhanced cooling is not desired.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: April 23, 2024
    Assignee: Ford Global Technologies, LLC
    Inventors: Patrick Gordon Collins, David Michael Horan, Thomas Karl Rothermel, Jacob Gregory Powers
  • ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
    Publication number: 20240067719
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: October 11, 2022
    Publication date: February 29, 2024
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWERS
  • Anti-human vista antibodies and use thereof
    Patent number: 11649283
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 16, 2023
    Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.
    Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
  • Anti-human vista antibodies and use thereof
    Patent number: 11603403
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 14, 2023
    Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV
    Inventors: Isabelle Lemercier, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers
  • Anti-human vista antibodies and use thereof
    Patent number: 11603402
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 14, 2023
    Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV
    Inventors: Catherine Carriere, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers
  • Anti-human VISTA antibodies and use thereof
    Patent number: 11525000
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 13, 2022
    Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.
    Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS
    Publication number: 20220144954
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 12, 2022
    Inventors: Linda Snyder, Gordon Powers
  • Anti-vista antibodies and fragments
    Patent number: 11242392
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 8, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
    Publication number: 20210347896
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 11, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS
    Publication number: 20210318322
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
    Publication number: 20210277110
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 9, 2021
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS, USES THEREOF, AND METHODS OF IDENTIFYING SAME
    Publication number: 20210171640
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Application
    Filed: November 25, 2020
    Publication date: June 10, 2021
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
    Patent number: 11014987
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Anti-VISTA antibodies and fragments
    Patent number: 11009509
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 18, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • Method of identifying anti-VISTA antibodies
    Patent number: 10899836
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 26, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
    Patent number: 10894830
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • ANTI-VISTA ANTIBODIES AND FRAGMENTS
    Publication number: 20200017589
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Application
    Filed: April 26, 2019
    Publication date: January 16, 2020
    Inventors: Linda Snyder, Gordon Powers
  • ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
    Publication number: 20190330349
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 31, 2019
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Dov PECHENICK, Linda SNYDER, Gordon POWERS
  • Anti-vista antibodies and fragments
    Patent number: 10273301
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: April 30, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Anti-VISTA Antibodies And Fragments
    Publication number: 20180306799
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Application
    Filed: June 23, 2016
    Publication date: October 25, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez